期刊文献+

Study of consolidation chemotherapy in advanced epithelial ovarian carcinoma

Study of consolidation chemotherapy in advanced epithelial ovarian carcinoma
下载PDF
导出
摘要 Objective:A prospective randomized study was designed to evaluate the role of consolidation chemotherapy in advanced epithelial ovarian carcinoma.Methods:50 patients with advanced epithelial ovarian carcinoma treated in our hospital during the period from March 2000 to October 2005 were enrolled in this study.All patients had achieved clinical complete remission by means of standard treatments,and were randomly divided into consolidation chemotherapy group and control group.Relapse rate,and disease-free survival(DFS)time were analyzed in both groups.Results:24 patients were assigned in consolidation chemotherapy group,and 26 patients in control group.Tumor relapse interval in consolidation group was(26.5±7.4)months,vs.(16.8±7.0)months in control group respectively,P=0.001.Time to relapse(TTR)in consolidation group was(19.2±6.8)months,vs.(10.0±6.9)months in control group,P=0.002.Analysis of DFS time and overall survival time,Log Rank test:P=0.042 and P=0.062,respectively.Conclusions:Consolidation chemotherapy could be the relevant factor that postpones tumor relapse interval and prolongs DFS time in advanced epithelial ovarian carcinoma patients who had achived chlinical complete remission.But so far the statistic result of our clinical study is beyond the conclusion that consolidation chemotherapy can decrease relapse rate or increase survival rate.Multicenter randomized clinical trial should be performed to confirm the role of consolidation chemotherapy in advanced epithelial ovarian carcinoma. Objective:A prospective randomized study was designed to evaluate the role of consolidation chemotherapy in advanced epithelial ovarian carcinoma. Methods: 50 patients with advanced epithelial ovarian carcinoma treated in our hospital during the period from March 2000 to October 2005 were enrolled in this study. All patients had achieved clinical complete remission by means of standard treatments, and were randomly divided into consolidation chemotherapy group and control group. Relapse rate, and disease-free survival(DFS) time were analyzed in both groups. Results: 24 patients were assigned in consolidation chemotherapy group, and 26 patients in control group. Tumor relapse interval in consolidation group was (26.5±7.4) months, vs. (16.8±7.0) months in control group respectively, P=0. 001. Time to relapse(TTR) in consolidation group was (19.2±6.8) months, vs. (10.0±6.9) months in control group, P=0. 002. Analysis of DFS time and overall survival time, Log Rank test:P=0. 042 and P = 0. 062, respectively. Conclusions: Consolidation chemotherapy could be the relevant factor that postpones tumor relapse interval and prolongs DFS time in advanced epithelial ovarian carcinoma patients who had achived chlinical complete remission. But so far the statistic result of our clinical study is beyond the conclusion that consolidation chemotherapy can decrease relapse rate or increase survival rate. Multicenter randomized clinical trial should be performed to confirm the role of consolidation chemotherapy in advanced epithelial ovarian carcinoma.
出处 《生殖医学杂志》 CAS 2007年第A01期60-65,共6页 Journal of Reproductive Medicine
关键词 化学疗法 卵巢癌 治疗方法 临床分析 Ovarian Carcinoma Consolidation therapy Chemotherapy Tumor Relapse Survival
  • 引文网络
  • 相关文献

参考文献16

  • 1Richard RB, Lois Almadrones RN, Ennapadam SV, et al. A Phase Ⅱ Trial of Intraperitoneal Cisplatin and Etoposide as Consolidation Therapy in Patients with Stage Ⅱ-Ⅳ Epithelial Ovarian Cancer Following Negative Surgical Assessment. Gynecol Oncol, 1998, 69:17-22.
  • 2Christophe T, Christophe L, Jean LM, et al. Intravenous Chemotherapy, Early Debulking Surgery, and Consolidation Intraperitoneal Chemotherapy in Advanced Ovarian Carcinoma. Gynecol Oncol, 2001, 83:198-204.
  • 3Rothenberg ML, Liu PY, Wilczynski S, et al. Phase Ⅱ Trial of Oral Altretamine for Consolidation of Clinical Complete Remission in Women with Stage Ⅲ Epithelial Ovarian Cancer:A Southwest Oncology Group Trial (SWOG-9326). Gynecol Oncol, 2001, 82:317-322.
  • 4Markman M, Liu PY, Wilczynski S, et al. Phase Ⅲ randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol, 2003, 21:2460-2465.
  • 5Placido SD, Scambia G, Vagno G, et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol, 2004, 22,2635-2642.
  • 6Piccart MJ, Floquet A, Scarfone G, et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase Ⅲ study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer, 2003, 13[suppl 2]:196-203.
  • 7Berek JS, Taylor PT, Gordon A, et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol, 2004, 22:3507-3516.
  • 8Uwe W, Siegmund K, Silke R, et al. Immunological Consolidation of Ovarian Carcinoma Recurrences with Monoclonal Anti-Idiotype Antibody ACA125: Immune Responses and Survival in Palliative Treatment. Clinical Cancer Research, 2001, 7:1154-1162.
  • 9Hellmuth P, Manfred L, Edgar P, et al. Consolidation Radiotherapy after Carboplatin-Based Chemotherapy in Radically Operated Advanced Ovarian Cancer. Gynecol Oncol, 1999, 72:215-219.
  • 10Erkan T, Yesim E, Sezer S, et al. Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer Consolidative intraperitoneal cisplatin in ovarian cancer. Gynecol Oncol, 2004, 92: 147-151.
;
使用帮助 返回顶部